tiprankstipranks
Trending News
More News >
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC
Advertisement

Benitec Biopharma (BNTC) AI Stock Analysis

Compare
282 Followers

Top Page

BNTC

Benitec Biopharma

(NASDAQ:BNTC)

Rating:47Neutral
Price Target:
$12.50
▲(4.95%Upside)
Benitec Biopharma's stock score is primarily driven by weak financial performance, reflected in large net losses and negative cash flow. The technical outlook is bearish, and valuation concerns arise from a negative P/E ratio. However, the recent positive corporate event provides a glimmer of potential growth, slightly boosting the score.
Positive Factors
Analyst Rating
Analyst reiterates Buy rating based on the promising results and progress of the BB-301 trials.
Clinical Trial Progress
BB-301 low-dose regimen continues to demonstrate promise, with increasing durability of response at latest update.
Financial Performance
Benitec Biopharma recorded a F3Q25 net loss of only $0.24 per share vs. the forecast of a net loss of $0.36 per share.
Negative Factors
Clinical Trial Risks
Risks include slower-than-expected progress in the ongoing clinical trial of BB-301 and the potential for emergence of unexpected side effects.

Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)

Benitec Biopharma Business Overview & Revenue Model

Company DescriptionBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
How the Company Makes MoneyBenitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary
Benitec Biopharma shows financial instability with significant losses and negative cash flow. The strong equity position and recent financing provide some support, but challenges in revenue generation and profitability remain. Continuous high cash burn poses a risk without substantial revenue improvement.
Income Statement
20
Very Negative
The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.
Balance Sheet
50
Neutral
Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.
Cash Flow
30
Negative
The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue216.00K75.00K73.00K59.00K97.00K
Gross Profit108.00K-306.00K64.00K-64.00K-171.06K
EBITDA-22.49M-18.70M-17.85M-13.60M-7.91M
Net Income-21.75M-19.56M-18.56M-13.78M-8.30M
Balance Sheet
Total Assets52.21M4.46M5.97M21.38M11.59M
Cash, Cash Equivalents and Short-Term Investments50.87M2.48M4.06M19.77M9.80M
Total Debt284.00K559.00K811.00K213.00K405.00K
Total Liabilities4.96M4.26M3.09M1.37M1.35M
Stockholders Equity47.25M202.00K2.88M20.01M10.24M
Cash Flow
Free Cash Flow-19.58M-18.01M-15.91M-13.05M-7.63M
Operating Cash Flow-19.40M-18.01M-15.90M-12.83M-7.54M
Investing Cash Flow-179.00K-1.00K-13.00K-221.00K-94.00K
Financing Cash Flow68.03M16.02M0.0022.52M1.77M

Benitec Biopharma Technical Analysis

Technical Analysis Sentiment
Negative
Last Price11.91
Price Trends
50DMA
13.85
Negative
100DMA
13.73
Negative
200DMA
12.32
Negative
Market Momentum
MACD
-0.69
Positive
RSI
42.91
Neutral
STOCH
25.95
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Negative. The current price of 11.91 is below the 20-day moving average (MA) of 12.32, below the 50-day MA of 13.85, and below the 200-day MA of 12.32, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 42.91 is Neutral, neither overbought nor oversold. The STOCH value of 25.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTC.

Benitec Biopharma Risk Analysis

Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Benitec Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (58)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$410.04M-22.95%40.88%-579.73%
58
Neutral
$653.45M-115.47%
58
Neutral
£4.95B6.56-62.36%103.85%34.03%6.31%
57
Neutral
$739.87M-83.24%-100.32%-197.69%
55
Neutral
$631.82M181.41%3055.71%-18.80%
47
Neutral
$311.07M-48.57%-100.00%83.98%
45
Neutral
$370.71M-1869.55%-60.19%56.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BNTC
Benitec Biopharma
11.91
2.51
26.70%
CKPT
Checkpoint Therapeutics
4.26
1.69
65.76%
ETON
Eton Pharmaceuticals
15.37
11.79
329.33%
PHAT
Phathom Pharmaceuticals
9.05
-2.69
-22.91%
AMLX
Amylyx Pharmaceuticals Inc
8.30
6.33
321.32%
ZBIO
Zenas BioPharma, Inc.
16.32
-1.65
-9.18%

Benitec Biopharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Benitec Biopharma Advances BB-301 Clinical Study
Positive
Jul 9, 2025

On July 9, 2025, Benitec Biopharma announced that the sixth and final subject of Cohort 1 was safely treated with a low dose of BB-301 in their Phase 1b/2a Clinical Treatment Study. Following a positive recommendation from the Data Safety Monitoring Board, the company plans to begin enrolling subjects for Cohort 2 in the fourth quarter of 2025. This development marks a significant step in advancing their gene therapy program, potentially enhancing Benitec’s position in the biotechnology industry and offering hope for stakeholders involved in the treatment of OPMD.

The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 19, 2025